IPO Tracker

image_pdf

Life sciences companies face unique issues in accessing capital markets, including matters related to due diligence, public relations, regulatory and intellectual property. Goodwin offers a team of sophisticated life sciences lawyers who have expertise with these issues and extensive experience across the full breadth of equity and debt capital markets, advising issuers, sponsors, underwriters and investors in a variety of transactions to ensure deals close smoothly and in a timely way.

With over 150 lawyers focused on serving over 600 life sciences clients, our integrated, full service life sciences team offers deep transactional expertise drawing on firm resources spread across the globe. Since 2010, the firm has advised on more than 150 emerging company IPOs raising an excess of $25 billion. Over the years, Goodwin has been ranked among the top law firms for biotech IPOs issuer representation. In the past two years, Goodwin has advised twenty three biotechnology issuers on their IPOs totaling an aggregate of $4.1 billion.

2021
2020

2021

Company Name
Therapeutic Focus; Treatment Type
Underwriters
IPO Date
Offer Price to the Public
Aggregate Offering Raise
Original Price Range
Goodwin Participation,
if applicable
Pyxis Oncology
(NASDAQ: PYXS)
Cancer; Biologics; Antibodies BofA Securities
Credit Suisse
Jefferies
LifeSci Capital
William Blair & Co.
10/7/2021
S-1
$16.00 $168 million $14 – $16
Theseus Pharmaceuticals, Inc.
(NASDAQ:
THRX)
Cancer; Transformative Targeted Therapies SVB Leerink
Cantor Fitzgerald
Jefferies
Wedbush Securities
10/6/2021
S-1
$16.00 $160 million $14 – $16
Dice Therapeutics
(NASDAQ: DICE)
Oral Therapeutics; Chronic Diseases SVB Leerink
Evercore
BofA Securities
9/14/2021
S-1
$17.00 $204 million $15 – $17
Eliem Therapeutics
(NASDAQ: ELYM)
CNS Disorders; Small Molecules SVB Leerink
Evercore
Stifel Nicolaus
Guggenheim
8/9/2021
S-1
$12.50 $92 million $17 – $19
Adagio Therapeutics
(NASDAQ: ADGI)
Infectious Diseases; Biologics Morgan Stanley
Jefferies
Stifel Nicolaus
Guggenheim
8/5/2021
S-1
$17 $355.8 million $16 – $18
Rani Therapeutics
(NASDAQ: RANI)
Rare Diseases; Drug Delivery BofA Securities
Stifel Nicolaus
Cantor Fitzgerald
Canaccord Genuity
7/30/2021
S-1
$11 $73.3 million $14 – $16 Underwriters
Immuneering
(NASDAQ: IMRX)
Cancer; Small Molecules Morgan Stanley
Jefferies
Cowen & Co.
Guggenheim
7/30/2021
S-1
$15 $129.4 million $14 – $16
Omega Therapeutics
(NASDAQ: OMGA)
Cancer; Biologics Goldman Sachs
Jefferies
Piper Sandler
7/30/2021
S-1
$17 $125.8 million $16 – $18 Underwriters
Tenaya Therapeutics
(NASDAQ: TNYA)
Heart Diseases; Gene Therapy Morgan Stanley
Cowen & Co.
Piper Sandler
7/30/2021
S-1
$15 $207 million $14 – $16
Nuvalent
(NASDAQ: NUVL)
Cancer; Small Molecules J.P. Morgan
Cowen
Piper Sandler
7/28/2021
S-1
$17 $190.6 million $16 – $18 Issuer
Icosavax
(NASDAQ: ICVX)
Infectious Diseases; Vaccines Jefferies
Cowen
Evercore
William Blair
7/28/2021
S-1
$15 $209.3 million $14 – $16
Rallybio
(NASDAQ: RLYB)
Rare Diseases; Biologics Jefferies
Cowen
Evercore
7/28/2021
S-1
$13 $92.7 million $13 – $15
Candel Therapeutics
(NASDAQ: CADL)
Cancer; Biologics Jefferies
Credit Suisse
BMO Capital Markets
UBS
7/26/2021
S-1
$8 $72 million $13 – $15 Issuer
Caribou Biosciences
(NASDAQ CRBU)
Cancer; Gene Therapy BofA Securities
Citigroup
SVB Leerink
7/22/2021
S-1
$16 $304 million $14 – $16
HCW Biologics
(NASDAQ: HCWB)
Cancer; Biologics EF Hutton 7/19/2021
S-1
$8 $56 million $8 – $10
Imago BioSciences
(NASDAQ: IMGO)
Cancer; Small Molecules Jefferies
Cowen & Co.
Stifel Nicolaus
Guggenheim
7/15/2021
S-1
$16 $134.4 million $14 – $16
TScan Therapeutics
(NASDAQ: TCRX)
Cancer; Cell Therapy Morgan Stanley
Jefferies
Cowen & Co.
Barclays Capital
7/15/2021
S-1
$15 $100 million $15 – $17
Erasca
(NASDAQ: ERAS)
Cancer; Small Molecules J.P. Morgan
Morgan Stanley
BofA Securities
Evercore
Guggenheim
7/15/2021
S-1
$16 $345 million $14 – $16
Acumen Pharmaceuticals (NASDAQ: ABOS) CNS Disorders; Antibodies BofA Securities
Credit Suisse
Stifel Nicolaus
UBS
6/30/2021
S-1
$16 $160 million $14 – $16
Aerovate Therapeutics
(NASDAQ: AVTE)
Heart diseases; Drug Delivery Jefferies
Cowen & Co.
Evercore
Wedbush PacGrow
6/29/2021
S-1
$14 $139.8 million $13 – $15 Issuer
GH Research
(NASDAQ: GHRS)
CNS Disorders; Small Molecules Cowen & Co.
Stifel Nicolaus
Canaccord Genuity
JMP Securities
6/24/2021
F-1
$16 $160 million $14 – $16
Graphite Bio
(NASDAQ: GRPH)
Rare Diseases; Gene Therapy Morgan Stanley
BofA Securities
Cowen & Co.
SVB Leerink
6/24/2021
S-1
$17 $273.7 million $15 – $17 Issuer
Elevation Oncology
(NASDAQ: ELEV)
Cancer; Antibodies J.P. Morgan
Cowen & Co.
SVB Leerink
Wedbush PacGrow
6/24/2021
S-1
$16 $100 million $15 – $17
Monte Rosa Therapeutics
(NASDAQ: GLUE)
Cancer; Small Molecules J.P. Morgan
Cowen & Co.
Piper Sandler
Guggenheim
6/23/2021
S-1
$19 $222.3 million $17 – $19 Issuer
Ambrx Biopharma
(NYSE: AMAM)
Cancer; Biologics Goldman Sachs
BofA Securities
Cowen & Co.
6/17/2021
F-1
$18 $126 million $17 – $19 Underwriters
atai Life Sciences
(NASDAQ: ATAI)
CNS Disorders; Small Molecules Credit Suisse
Citigroup
Cowen & Co.
Berenberg Capital Markets Cantor Fitzgerald
RBC Capital Markets
Canaccord Genuity
6/17/2021
S-1
$15 $225 million $13 – $15
Cyteir Therapeutics
(NASDAQ: CYT)
Cancer; Small Molecules J.P. Morgan
Morgan Stanley
BofA Securities
Wedbush PacGrow
6/17/2021
S-1
$18 $133.3 million $16 – $18
Century Therapeutics
(NASDAQ: IPSC)
Cancer; Cell Therapy J.P. Morgan
BofA Securities
SVB Leerink
Piper Sandler
6/17/2021
S-1
$20 $242.7 million $18 – $20
Lyell Immunopharma
(NASDAQ: LYEL)
Cancer; Cell Therapy Goldman Sachs
BofA Securities
J.P. Morgan
Morgan Stanley
6/16/2021
S-1
$17 $425 million $16 – $18
Verve Therapeutics
(NASDAQ: VERV)
Heart Diseases; Gene Therapy J.P. Morgan
Jefferies
Guggenheim
William Blair
6/16/2021
S-1
$19 $306.7 million $16 – $18
Molecular Partners
(NASDAQ: MOLN)
Infectious Diseases; Biologics J.P. Morgan
SVB Leerink
Cowen & Co.
RBC Capital Markets
Kempen & Co.
6/15/2021
F-1
$21.25 $63.8 million $27.14  
Janux Therapeutics
(NASDAQ: JANX)
Cancer; Biologics BofA Securities
Cowen & Co.
Evercore
H.C. Wainwright
6/10/2021
S-1
$17 $222.9 million $15-$17  
Centessa Pharmaceuticals
(NASDAQ: CNTA)
Cancer; Small Molecules Morgan Stanley
Goldman Sachs
Jefferies
Evercore
5/27/2021
S-1
$20 $379.5 million $18 – $20 Issuer
Day One Biopharmaceuticals
(NASDAQ: DAWN)
Cancer; Small Molecules J.P. Morgan
Cowen & Co.
Piper Sandler
Wedbush PacGrow
5/26/2021
S-1
$16 $184 million $14 – $16
Talaris Therapeutics
(NASDAQ: TALS)
Immune Diseases; Cell Therapy Morgan Stanley
SVB Leerink
Evercore
Guggenheim
5/6/2021
S-1
$17 $150 million $16 – $18 Issuer
Valneva
(NASDAQ: VALN)
Infectious Diseases; Vaccines Goldman Sachs
Jefferies
Guggenheim
Bryan, Garnier & Co.
5/6/2021
F-1
$26.41 $107.6 million $24.04 – $28.85 Underwriters
Werewolf Therapeutics
(NASDAQ: HOWL)
Cancer; Biologics Jefferies
SVB Leerink
Evercore
H.C. Wainwright
4/29/2021
S-1
$16 $120 million $15 – $17
Vaccitech
(NASDAQ: VACC)
Infectious Diseases; Vaccines Morgan Stanley
Jefferies

Barclays
William Blair
H.C. Wainwright
4/29/2021
S-1
$17 $110.5 million $16 – $18 Issuer
Impel NeuroPharma
(NASDAQ: IMPL)
CNS Disorders; Drug Delivery Cowen & Co.
Guggenheim
Wedbush PacGrow
4/22/2021
S-1
$15 $80 million $14 – $16
Rain Therapeutics
(NASDAQ: RAIN)
Cancer; Small Molecules Goldman Sachs
Citigroup

Piper Sandler
Guggenheim 
4/22/2021
S-1
$17 $125 million $16 – $18
Biomea Fusion
(NASDAQ: BMEA)
Cancer; Small Molecules J.P. Morgan
Jefferies
Piper Sandler
4/15/2021
S-1
$17 $153 million $15 – $17
Recursion Pharmaceuticals
(NASDAQ: RXRX)
Rare Diseases; Small Molecules Goldman Sachs
J.P. Morgan
BofA Securities
SVB Leerink
Allen & Company
KeyBanc Capital Markets
4/15/2021
S-1
$18 $501.8 million $16 – $18
Reneo Pharmaceuticals
(NASDAQ: RPHM)
Rare Diseases; Small Molecules Jefferies
SVB Leerink
Piper Sandler
4/8/2021
S-1
$15 $93.8 million $15 – $17
VectivBo
(NASDAQ: VECT)
Rare Diseases; Biologics BofA Securities
SVB Leerink
Credit Suisse
LifeSci Capital
4/8/2021
F-1
$17 $146.6 million $16 – $18
Achilles Therapeutics
(NASDAQ: ACHL)
Cancer; Cell Therapy J.P. Morgan
BofA Securities
Piper Sandler
Chardan Capital Markets
Oppenheimer
Kempen & Co
3/30/2021
F-1
$18 $175.5 million $17 – $19 Issuer
Design Therapeutics
(NASDAQ: DSGN)
Rare Diseases; Small Molecules Goldman Sachs
SVB Leerink
Piper Sandler
3/25/2021
S-1
$20 $276 million $18 – $20
Edgewise Therapeutics
(NASDAQ: EWTX)
Rare Diseases; Small Molecules J.P. Morgan
Goldman Sachs
SVB Leerink
3/25/2021
S-1
$16 $202.4 million $14 – $16
Ikena Oncology
(NASDAQ: IKNA)
Cancer; Small Molecules Jefferies
Cowen & Co.
Credit Suisse
William Blair
3/25/2021
S-1
$16 $143.8 million $15 – $17 Issuer
LAVA Therapeutics
(NASDAQ: LVTX)
Cancer; Antibodies J.P. Morgan
Jefferies
SVB Leerink
3/24/2021
F-1
$15 $100.5 million $14 – $16
Connect Biopharma
(NASDAQ: CNTB)
Immune Diseases; Antibodies Jefferies
SVB Leerink
Piper Sandler
China International Capital Corporation
3/18/2021
F-1
$17 $219.9 million $15 – $17
Instil Bio
(NASDAQ: TIL)
Cancer; Cell Therapy Morgan Stanley
Jefferies
Cowen & Co. 
3/18/2021
S-1
$20 $368 million $17 – $19
Finch Therapeutics
(NASDAQ: FNCH)
Immune Diseases; Biologics BofA Securities
Jefferies
Evercore
3/18/2021
S-1
$17 $127.5 million $15 – $17 Underwriters
Prometheus Biosciences
(NASDAQ: RXDX)
Immune Diseases; Antibodies SVB Leerink
Credit Suisse
Stifel Nicolaus
Guggenheim
3/11/2021
S-1
$19 $218.5 million $16 – $18
Longboard Pharmaceuticals
(NASDAQ: LBPH)
CNS Disorders; Small Molecules Citigroup
Evercore
Guggenheim
Cantor Fitzgerald
3/11/2021
S-1
$16 $80 million $14 – $16
NexImmune
(NASDAQ: NEXI)
Cancer; Cell Therapy Barclays Capital
Cantor Fitzgerald
Raymond James
Allen & Company
2/11/2021
S-1
$17 $126.5 million $15 – $17
Decibel Therapeutics
(NASDAQ: DBTX)
Ear Diseases; Gene Therapy Citigroup
SVB Leerink
BMO Capital Markets
Barclays Capital
2/11/2021
S-1
$18 $127 million $16 – $18 Underwriter
Adagene
(NASDAQ: ADAG)
Cancer; Antibodies Goldman Sachs (Asia)
Morgan Stanley
Jefferies

China Renaissance Securities (Hong Kong)
2/08/2021
F-1
$19 $161 million $17 – $19
 

Vor Biopharma
(NASDAQ: VOR)

 

Cancer; Cell Therapy Goldman Sachs
Evercore

Barclays Capital
Stifel Nicolaus
2/05/2021
S-1
$18 $203.4 million $16 – $18
 

Angion Biomedica
(NASDAQ: ANGN)

 

Kidney Diseases; Small Molecules Cowen & Co.
Stifel Nicolaus
H.C. Wainwright
Oppenheimer
2/04/2021
S-1
$16 $92 million $14 – $16
 

Bolt Biotherapeutics
(NASDAQ: BOLT)

 

Cancer; Biologics Morgan Stanley
SVB Leerink
Stifel Nicolaus
Guggenheim
2/04/2021
S-1
$20 $264.5 million $16 – $18
 

Immunocore
(NASDAQ: IMCR)

 

Cancer; Cell Therapy Goldman Sachs
J.P. Morgan
Jefferies
2/04/2021
F-1
$26 $297.1 million $23 – $25
 

Pharvaris
(NASDAQ: PHVS)

 

Rare Diseases; Small Molecules Morgan Stanley
BofA Securities
Sunrise Securities
Oppenheimer
Kempen & Co
2/04/2021
F-1
$20 $190.2 million $17 – $19
 

Terns Pharmaceuticals
(NASDAQ: TERN)

 

Liver Diseases; Small Molecules J.P. Morgan
Goldman Sachs
Cowen & Co.
2/04/2021
S-1
$17 $146.6 million $15 – $17
 

Sensei Biotherapeutics
(NASDAQ: SNSE)

 

Cancer; Biologics Citigroup
Piper Sandler
Berenberg Capital Markets Oppenheimer
2/03/2021
S-1
$19 $152.6 million $16 – $18 Underwriters
 

Landos Biopharma
(NASDAQ: LABP)

 

Immune Diseases; Small Molecules J.P. Morgan
Jefferies
SVB Leerink
Raymond James
2/03/2021
S-1
$16 $100 million $15 – $17
 

Sana Biotechnology
(NASDAQ: SANA)

 

Cancer; Cell Therapy Morgan Stanley
Goldman Sachs
J.P. Morgan
BofA Securities
2/03/2021
S-1
$25 $675.6 million $20 – $23
Cullinan Management
(NASDAQ: CGEM)
Cancer; Biologics Morgan Stanley
SVB Leerink
Evercore
H.C. Wainwright
1/07/2021
S-1
$21 $287.4 million $17 – $19 Issuer
Gracell Biotechnologies
(NASDAQ: GRCL)
Cancer; Cell Therapy Citigroup
Jefferies
Piper Sandler
Wells Fargo
1/07/2021
F-1
$19 $209 million $16 – $18

2020

Company Name
Company
Focus
Underwriters
IPO Date
Offer Price to the Public
Aggregate Offering Raise
Original Price Range
Goodwin Participation,
if applicable
BioAtla
(NASDAQ: BCAB)
Therapies for solid tumor cancer J.P. Morgan
Jefferies
Credit Suisse
12/15/2020
S-1
$18 $217.4 million $15 – $17
AbCellera Biologics
(NASDAQ: ABCL)
AI-powered drug discovery platform Credit Suisse
Sifel Nicolaus
Berenberg Capital Markets
SVB Leerink
BMO Capital Markets
12/10/2020
S-1
$20 $555.5 million $14-$17 Issuer
4D Molecular Therapeutics
(NASDAQ: FDMT)
Gene therapies to treat diseases Goldman Sachs
BofA Securities
Evercore
12/10/2020
S-1
$23 $222 million $20 – $22
Nanobiotix
(NASDAQ: NBTX)
Nanotech to help treat cancer Jefferies
Evercore
UBS
12/10/2020
F-1
$11.14 $100.4 million $14.69
Seer
(NASDAQ: SEER)
Protein profiling technologies J.P. Morgan
Morgan Stanley
BofA Securities
Cowen & Co.
12/03/2020
S-1
$19 $201.3 million $16-$18
Sigilon Therapeutics
(NASDAQ: SGTX)
Therapies for chronic diseases Morgan Stanley
Jefferies
Barclays Capital
Canaccord Genuity
12/03/2020
S-1
$18 $144.9 million $17 – $19
Silverback Therapeutics (NASDAQ: SBTX) Tissue targeted therapeutics for cancer Goldman Sachs
SVB Leerink
Stifel Nicolaus
12/03/2020
S-1
$21 $277.7 million $17-$19
Kinnate Biopharma
(NASDAQ: KNTE)
Genomically defined cancer therapeutics Goldman Sachs
SVB Leerink
Piper Sandler
12/02/2020
S-1
$20 $276 million $16-$18
Maravai LifeSciences (NASDAQ: MRVI) Products in support of biopharma R&D Morgan Stanley
Jefferies
Goldman Sachs
11/19/2020
S-1
$27 $1.86 billion $24 – $27
Olema Pharmaceuticals (NASDAQ: OLMA) Therapies for women’s cancers J.P. Morgan
Jefferies
Cowen & Co.
Canaccord Genuity
11/18/2020
S-1
$19 $240.4 million $16 – $18
Atea Pharmaceuticals
(NASDAQ: AVIR)
Antiviral therapeutics J.P. Morgan
Morgan Stanley
Evercore
William Blair
10/29/2020
S-1
$24 $345 million $22 – $24
SQZ Biotechnologies
(NYSE: SQZ)
Cell therapies for cancer BofA Securities
Evercore
Stifel Nicolaus
BTIG
10/29/2020
S-1
$16 $81 million $16 – $18 Underwriter
Galecto
(NASDAQ: GLTO)
Therapeutics for fibrotic diseases BofA Securities
SVB Leerink
Credit Suisse
10/28/2020
S-1
$15 $85 million $14 – $16 Issuer
Foghorn Therapeutics
(NASDAQ: FHTX)
Gene expression to battle cancer Goldman Sachs
Morgan Stanley
Cowen & Co.
10/22/2020
S-1
$16 $120 million $15-$17
Abcam
(NASDAQ: ABCM)
Medical reagents & diagnostics Morgan Stanley
BofA Securities
SVB Leerink
Lazard Freres
William Blair
10/21/2020
F-1
$17.50 $180 million $16.52
Opthea
(NASDAQ: OPT)
Therapies for retinal diseases Citigroup
SVB Leerink
Oppenheimer
Truist Securities
10/16/2020
F-1
$13.50 $128.2 million $17.26 Underwriter
Aligos Therapeutics
(NASDAQ: ALGS)
Therapeutics for viral and liver diseases J.P. Morgan
Jefferies
Piper Sandler
Cantor Fitzgerald
10/15/2020
S-1
$15 $150 million $15-$16
Praxis Precision Medicines
(NASDAQ: PRAX)
Central nervous system therapies Cowen & Co.
Evercore
Piper Sandler
Wedbush PacGrow
10/15/2020
S-1
$19 $218.5 million $16-$18 Issuer
Codiak Biosciences
(NASDAQ: CDAK)
Therapeutics using exosome biology Goldman Sachs
Evercore
William Blair
Wedbush PacGrow
10/13/2020
S-1
$15 $82.5 million $14-$16 Issuer
Kronos Bio
(NASDAQ: KRON)
Cancer therapeutics Goldman Sachs
Jefferies
Cowen & Co.
Piper Sandler
10/8/2020
S-1
$19 $287.5 million $16-$18
Shattuck Labs
(NASDAQ: STTK)
Immuno-oncology protein therapies Citigroup
Cowen & Co.
Evercore
Needham
10/8/2020
S-1
$17 $232.3 million $14-$16
Spruce Biosciences
(NASDAQ: SPRB)
Endocrine disorder therapies Cowen & Co.
SVB Leerink
Credit Suisse
RBC Capital Markets
10/8/2020
S-1
$15 $103.5 million $14-$16
Aziyo Biologics
(NASDAQ: AZYO)
Tissue regenerating medical products Piper Sandler
Cowen & Co.
Cantor Fitzgerald
Truist Securities
10/7/2020
S-1
$17 $50 million $16-$18
C4 Therapeutics
(NASDAQ: CCCC)
Drugs to destroy target proteins Jefferies
Evercore
BMO Capital Markets
UBS
10/1/2020
S-1
$19 $209.76 million $16-$18 Issuer
Immunome
(NASDAQ: IMNM)
Antibody therapeutics Ladenburg Thalmann
Chardan Capital Markets
10/1/2020
S-1
$12 $44.85 million $11-$13 Underwriter
Oncorus
(NASDAQ: ONCR)
Viral immunotherapies for cancer Jefferies
Evercore
Piper Sandler
10/1/2020
S-1
$15 $87 million $14-$16
Orphazyme
(NASDAQ: ORPH)
Neurodegenerative disease therapies BofA Securities
Cowen & Co.
Guggenheim
Danske Markets
9/28/2020
F-1
$11 $50.17 million $13.13
Graybug Vision
(NASDAQ: GRAY)
Medicines to treat ocular diseases SVB Leerink
Piper Sandler
9/24/2020
S-1
$16 $90 million $15-$17
PMV Pharmaceuticals (NASDAQ: PMVP) Tumor-agnostic cancer therapies Goldman Sachs
BofA Securities
Cowen & Co.
Evercore
9/24/2020
S-1
$18 $243.53 million $16-$18
Prelude Therapeutics (NASDAQ: PRLD) Small molecule cancer therapies Morgan Stanley
Goldman Sachs
BofA Securities
9/24/2020
S-1
$19 $181.90 million $17-$19
Taysha Gene Therapies
(NASDAQ: TSHA)
Therapies for monogenic diseases Goldman Sachs
Morgan Stanley
Jefferies
9/23/2020
S-1
$20 $181 million $18-$20 Underwriter
Athira Pharma
(NASDAQ: ATHA)
Therapeutics for neurological diseases Goldman Sachs
Jefferies
Stifel Nicolaus
9/17/2020
S-1
$17 $204 million $15-$17
COMPASS Pathways
(NASDAQ: CMPS)
Psilocybin therapies for depression Cowen & Co.
Evercore
Berenberg Capital Markets
9/17/2020
F-1
$17 $146.60 million $14-$16 Issuer
Dyne Therapeutics
(NASDAQ: DYN)
Therapies for genetic muscular diseases J.P. Morgan
Jefferies
Piper Sandler
Stifel Nicolaus
9/16/2020
S-1
$19 $268 million $16-$18
Metacrine
(NASDAQ: MTCR)
Liver and gastrointestinal therapies Jefferies
Evercore
RBC Capital Markets
Canaccord Genuity
9/15/2020
S-1
$13 $85.02 million $12-$14
Kymera Therapeutics (NASDAQ: KYMR) Small molecule protein degraders Morgan Stanley
BofA Securities
Cowen & Co.
Guggenheim
8/20/2020
S-1
$20 $199.75 million $16-$18 Issuer
Harmony Biosciences (NASDAQ: HRMY) Therapies for neurological disorders Goldman Sachs
Jefferies
Piper Sandler
8/18/2020
S-1
$24 $147.62 million $20-$23 Underwriter
Inhibrx
(NASDAQ: INBX)
Protein therapies to treat cancer Jefferies
Evercore
Credit Suisse
8/18/2020
S-1
$17 $136.85 million $16-$18
CureVac
(NASDAQ: CVAC)
Messenger RNA-based therapies BofA Securities
Jefferies
Credit Suisse
8/13/2020
F-1
$16 $245.33 million $14-$16
Checkmate Pharmaceuticals
(NASDAQ: CMPI)
Therapeutics to treat cancer BofA Securities
Jefferies
BMO Capital Markets
8/06/2020
S-1
$15 $75 million $14-$16 Issuer
Freeline Therapeutics
(NASDAQ: FRLN)
Gene therapies for monogenic diseases J.P. Morgan
Morgan Stanley
Evercore
8/06/2020
F-1
$18 $158.82 million $16-$18 Underwriter
Acutus Medical
(NASDAQ: AFIB)
Cardiac arrhythmia treatments J.P. Morgan
BofA Securities
William Blair
8/05/2020
S-1
$18 $182.64 million $16-$18
Oak Street Health
(NYSE: OSH)
Healthcare for adults on Medicare J.P. Morgan
Goldman Sachs
Morgan Stanley
8/05/2020
S-1
$21 $377.34 million $15-$17
AlloVir
(NASDAQ: ALVR)
Allogenic T cell therapies Morgan Stanley
J.P. Morgan
SVB Leerink
Piper Sandler
7/29/2020
S-1
$17 $317.68 million $16-$18 Issuer
Annexon
(NASDAQ: ANNX)
Complement-mediated disorder therapies J.P. Morgan
BofA Securities
Cowen & Co.
7/23/2020
S-1
$17 $288.36 million $14-$16
Inozyme Pharma
(NASDAQ: INZY)
Treatments for abnormal mineralization BofA Securities
Cowen & Co.
Piper Sandler
7/23/2020
S-1
$16 $128.8 million $14-$16
iTeos Therapeutics
(NASDAQ: ITOS)
Immuno-oncology therapeutics J.P. Morgan
SVB Leerink
Piper Sandler
7/23/2020
S-1
$19 $231.31 million $16-$18 Issuer
Nurix Therapeutics
(NASDAQ: NRIX)
Small molecule immuno-oncology agents J.P. Morgan
Piper Sandler
Stifel Nicolaus
7/23/2020
S-1
$19 $240.35 million $16-$18
ALX Oncology
(NASDAQ: ALXO)
Immuno-oncology therapies Jefferies
Credit Suisse
Piper Sandler
Cantor Fitzgerald
7/16/2020
S-1
$19 $185.7 million $15-$17
Berkeley Lights
(NASDAQ: BLI)
Biotherapeutics and cell-based products J.P. Morgan
Morgan Stanley
Cowen & Co.
7/16/2020
S-1
$22 $204.9 million $16-$18
Pandion Therapeutics
(NASDAQ: PAND)
Therapeutics for autoimmune diseases Goldman Sachs
Morgan Stanley
SVB Leerink
BMO Capital Markets
7/16/2020
S-1
$18 $135 million $16-$18 Underwriter
Renalytix AI
(NASDAQ: RNLX)
AI-enabled in vitro diagnostics J.P. Morgan
Sitfel Nicolaus
7/16/2020
F-1
$13.50 $85.1 million $14.22 Underwriter
Relay Therapeutics
(NASDAQ: RLAY)
Small molecule therapeutics for cancer J.P. Morgan
Goldman Sachs
Cowen & Co. Guggenheim
7/15/2020
S-1
$20 $460 million $16-$18 Issuer
Inventiva
(NASDAQ: IVA)
Non-alcoholic fatty liver treatments Jefferies
Stifel Nicolaus
Guggenheim 
7/09/2020
F-1
$14.40 $123.8 million $13.68
NKarta
(NASDAQ: NKTX)
Natural killer cell cancer therapies Cowen & Co.
Evercore
Stifel Nicolaus
Mizuho 
7/09/2020
S-1
$18 $289.8 million $14-1$16
Poseida Therapeutics
(NASDAQ: PSTX)
Cell and gene therapeutics BofA Securities
Piper Sandler
William Blair
7/09/2020
S-1
$16 $257.6 million $14-$16
Akouos, Inc.
NASDAQ (AKUS)
Gene therapies for hearing loss BofA Securities
Cowen & Co.
Piper Sandler
06/25/2020
S-1
$17.00 $244.37
million
$14.00 –
$16.00
 
Forma Therapeutics Holdings, Inc.
NASDAQ (FMTX)
Cancer & hematologic disease therapies Jefferies
SVB Leerink
Credit Suisse
06/25/2020
S-1
$20.00 $319.29
million
$16.00 –
$18.00
Issuer
PolyPid Ltd.
NASDAQ (PYPD)
Therapies to improve surgical outcomes Barclays Capital
BMO Capital Markets
Raymond James
06/25/2020
F-1 
$16.00  $69.00
million  
$15.00 –
$17.00 
 
Progenity, Inc.
NASDAQ (PROG)
Molecular testing products Piper Sandler
Wells Fargo Securities
06/19/2020
S-1
$15.00 $115.00
million
$14.00 –
$16.00 
 
Repare Therapeutics Inc.
NASDAQ (RPTX)
Genomic-focused cancer therapies Morgan Stanley
Goldman Sachs
Cowen & Co.
Piper Sandler
06/18/2020
S-1
$20.00 $253.00
million
$16.00 –
$18.00
Underwriter
Genetron Holdings Limited
NASDAQ (GTH)
Cancer molecular profiling technologies Credit Suisse
China International Capital Corporation
06/18/2020
F-1
$16.00 $294.4
million
$11.50 –
$13.50
 
Royalty Pharma plc
NASDAQ (RPRX)
Biopharmaceutical royalties acquisition J.P. Morgan
Morgan Stanley
BofA Securities
Goldman Sachs
Citigroup
UBS Securities
06/15/2020
S-1
$28.00 $2.5
billion
$25.00 –
$28.00
Underwriter
Avidity Biosciences, Inc.
NASDAQ (RNA)
Therapeutics to treat serious diseases Cowen & Co.
SVB Leerink
Credit Suisse
Wells Fargo Securities
06/11/2020
S-1
$18.00 $298.08
million
$14.00 –
$16.00 
 
Burning Rock Biotech Limited
NASDAQ (BNR)
Cancer therapy selection services Morgan Stanley
BofA Securities
Cowen & Co.
06/11/2020
F-1
$16.50 $256.16
million
$13.50 –
$15.50 
 
Generation Bio Co.
NASDAQ (GBIO)
Non-viral gene therapies J.P. Morgan
Jefferies
Cowen & Co.
Wedbush Securities
06/11/2020
S-1
$19.00 $229.99
million
$16.00 –
$18.00 
 
Vaxcyte, Inc.
NASDAQ (PCVX)
Pneumococcal conjugate vaccines BofA Securities
Jefferies
Evercore
06/11/2020
S-1
$16.00 $287.50
million
$14.00 –
$16.00 
 
Fusion Pharmaceuticals Inc.
NASDAQ (FUSN)
Radiopharmaceuticals to treat cancers Morgan Stanley
Jefferies
Cowen & Co.
06/05/2020
S-1
$17.00 $244.37
million
$14.00 –
$16.00
Issuer
Legend Biotech Corporation
NASDAQ (LEGN)
Cell therapies to treat cancer Morgan Stanley
J.P. Morgan
Jefferies
06/05/2020
F-1
$23.00  $487.34
million
$18.00 –
$20.00  
 
Applied Molecular Transport Inc.
NASDAQ (AMTI)
Oral biologic products to treat disease BofA Securities
Jefferies
SVB Leerink
06/04/2020
S-1
$14.00 $177.10 million $12.00 – $14.00   
Calliditas Therapeutics
NASDAQ (CALT)
Treatment for  autoimmune renal disease  Citigroup
Jefferies
Stifel Nicolaus 
06/04/2020
F-1 
$19.50 $90.00
million  
$19.77 Issuer
Pliant Therapeutics, Inc. 
NASDAQ (PLRX)
Fibrosis therapeutics Citigroup
Cowen & Co.
Piper Sandler
06/02/2020
S-1
$16.00 $165.60
million
$14.00-
$16.00
Issuer
Inari Medical, Inc.
NASDAQ (NARI)
Thrombectomy devices BofA Securities
Morgan Stanley
05/21/2020
S-1
$19.00 $179.22
million
$14.00 –
$16.00 
 
ADC Therapeutics SA
NASDAQ (ADCT)
Blood cancer therapies Morgan Stanley
BofA Securities
Cowen & Co.
05/14/2020
F-1
$19.00 $267.56
million
$16.00 –
$18.00 
 
Ayala Pharmaceuticals, Inc.
NASDAQ (AYLA)
Small molecule therapies for cancer Citigroup
Jefferies
05/07/2020
S-1
$15.00 $63.25
million
$14.00-
$16.00 
 
Lyra Therapeutics, Inc.
NASDAQ (LYRA)
Localized ear, nose & throat treatments BofA Securities
Jefferies
William Blair
04/30/2020
S-1
$16.00 $64.40
million
$14.00 –
$16.00 
 
ORIC Pharmaceuticals, Inc.
NASDAQ (ORIC)
Therapies to treat cancer J.P. Morgan
Citigroup
Jefferies
Guggenheim 
04/23/2020
S-1
$16.00 $138.00
million
$14.00-
$16.00 
 
Keros Therapeutics, Inc.
NASDAQ (KROS)
Treatment for hematological disorders Jefferies
SVB Leerink
Piper Sandler
04/07/2020
S-1
$16.00 $110.40
million
$14.00-
$16.00 
 
Zentalis Pharmaceuticals, Inc.
NASDAQ (ZNTL)
Small molecule cancer therapies Morgan Stanley
Jefferies
SVB Leerink
Guggenheim 
04/02/2020
S-1
$18.00 $190.02
million
$16.00 –
$18.00 
 
IMARA Inc.
NASDAQ (IMRA)
Therapies for hemoglobinopathies Morgan Stanley
Citigroup
SVB Leerink
03/11/2020
S-1
$16.00 $86.48
million
$16.00 –
$18.00 
 
Passage Bio, Inc.
NASDAQ (PASG)
CNS disorder therapies J.P. Morgan
Goldman Sachs
Cowen & Co.
02/27/2020
S-1
$18.00 $248.4
million
$16.00 –
$18.00 
 
Revolution Medicines, Inc.
NASDAQ (RVMD)
Protein therapies to treat cancer J.P. Morgan
Cowen & Co.
SVB Leerink
Guggenheim 
02/12/2020
S-1
$17.00 $273.7
million
$14.00-
$16.00 
 
Beam Therapeutics, Inc.
NASDAQ (BEAM)
Gene Editing J.P. Morgan
Jefferies
Barclays Capital
02/05/2020
S-1
$17.00 $207
million
$15.00 –
$17.00
 
PPD, Inc.
NASDAQ (PPD)
Drug development & laboratory svcs Barclays Capital
J.P. Morgan
Morgan Stanley
Goldman Sachs 
02/05/2020
S-1
$27.00 $1.80
billion
$24.00 –
$27.00
 
1Life Healthcare
NASDAQ (ONEM)
Digital healthcare platform J.P. Morgan
Morgan Stanley
01/30/2020
S-1
$14.00 $281.00
million
$14.00 –
$16.00
 
Arcutis Biotherapeutics, Inc.
NASDAQ (ARQT)
Treatments for dermatological diseases Goldman Sachs
Cowen & Co.
Guggenheim
01/30/2020
S-1
$17.00 $183.28
million
$15.00 –
$17.00
 
Black Diamond Therapeutics
NASDAQ (BDTX)
Small molecule tumor-agnostic therapies J.P. Morgan
Jefferies
Cowen & Co.
01/29/2020
S-1
$19.00 $231.3
million
$16.00 –
$18.00
Issuer
I-Mab
NASDAQ (IMAB)
Drugs for cancers & autoimmune diseases Jefferies
China International Capital Corporation
01/16/2020
F-1
$14.00 $119.25
million
$12.00 –
$15.00